OtherCancer_ESMO

Access to first-line recommended treatment for metastatic melanoma is denied to over 5,000 patients (70%) in Eastern and South-Eastern Europe, highlighting wide inequalities in treatment across the continent, according to figures from a survey of 30 countries.

ORR of active agents in locally advanced or metastatic breast cancer progressively decline with each successive therapy line used, according to results of the Spanish CASCADE study.

Ipilimumab, used in the adjuvant setting after complete resection of stage III melanoma, demonstrated prolonged overall survival (OS), distant metastasis free survival (DMFS), and relapse-free survival (RFS), according to the latest data from the EORTC 18071 trial.

Regorafenib, an oral multikinase inhibitor, was found by new research to be effective and safe in patients with HCC who progress on prior sorafenib treatment, leading to a statistically significant and clinically meaningful improvement in overall survival (OS).

It’s where ‘Epigenetics meets oncology,’ VolitionRx stated when describing their recently developed test, NuQTM, an epigenetic immunoassay for the detection of CRC. Results presented at the 2016 European Society for Medical Oncology Congress suggest that the method could reduce capacity pressures for colonoscopies and, possibly, detect more CRC cases early due to a higher throughput of patients.

A critical look at trials that tested immunotherapy and targeted therapies found that AEs are not reported to an acceptable standard, explained Dr Paolo Bossi, Medical Oncologist, Istituto Nazionale Tumori, Milan, Italy. His research, presented at the Congress of the European Society for Medical Oncology, October 2016, underlined that current reporting is in need of improvement.

Results from the largest study of a programmed death (PD)-1 inhibitor in bladder cancer to date, CheckMate 275, were presented at this year’s European Society for Medical Oncology, Copenhagen. The efficacy of nivolumab, a monoclonal antibody that inhibits the PD-1 signalling pathway, was studied in a total of 270 patients with advanced/ unresectable mUC.

At the 2016 Annual Congress of the European Society for Medical Oncology (ESMO) Dr Toni Choueiri, Director of the Kidney Cancer Center, Dana-Farber Cancer Institute, Boston, presented data which could have implications for how mRCC is treated first line. Dr Choueiri summaries the results by stating “cabozantinib did improve progression-free survival and overall response compared to sunitinib.”

Ipilimumab, used in the adjuvant setting after complete resection of stage III melanoma, demonstrated prolonged overall survival (OS), distant metastasis free survival (DMFS), and relapse-free survival (RFS), according to the latest data from the EORTC 18071 trial ...